BMS Expands Collaboration with CytomX for US$200 M Upfront

By Natasha Piper

Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)

Published: 8 Apr-2017

DOI: 10.3833/pdr.v2017.i4.2238     ISSN: 1756-7874

Section: Licensing

Fulltext:

Abstract

Bristol-Myers Squibb (BMS) has expanded its strategic collaboration with CytomX Therapeutics to discover novel therapies that will include up to eight additional oncology and non-oncology targets using CytomX’s proprietary Probody™ antibody platform...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details